Global Retinoblastoma Treatment Market 2015-2019


◆タイトル:Global Retinoblastoma Treatment Market 2015-2019
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥272,500見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥327,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About retinoblastoma
Cancer occurs when normal cells transform to evade the regular cell cycle process. Retinoblastoma is a rare eye cancer. It occurs in children of age less than 15 years; the disease is common in children younger than five years, especially children less than two years. The disease affects the retina and is caused by a mutation in the gene RB1. It usually appears in one eye and gradually spreads to the other. Clinically, retinoblastoma is classified into two: unilateral retinoblastoma, tumor in one eye, and bilateral retinoblastoma, tumor in both the eyes.

Technavio’s analysts forecast the global retinoblastoma market to grow at a CAGR of 3.57% over the period 2014-2019.

[Covered in this report]
The report includes the present scenario and the growth prospects of the global retinoblastoma market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of retinoblastoma.

Technavio’s report, Global Retinoblastoma Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the market segmentation. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas

[Key vendors]
• Baxter
• Bristol-Myers Squibb
• GlaxoSmithKline
• Spectrum Pharmaceuticals

[Other prominent vendors]
• BioLineRx
• Cellceutix
• Icon Bioscience
• Neotropix
• RXi Pharmaceuticals
• Recombio

[Market Driver]
• Increasing public awareness
• For a full, detailed list, view our report

[Market challenge]
• Treatment abandonment
• For a full, detailed list, view our report

[Market trend]
• Localized treatment approach
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?


01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology


06.Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.3 Classification
06.3.1 Bilateral Retinoblastoma
06.3.2 Unilateral Retinoblastoma
06.4 Symptoms
06.5 Diagnosis
06.5.1 Patient Examination
06.5.2 Imaging Tests
06.5.3 Biopsy Tests
06.5.4 Clinical Tests
06.6 Epidemiology
06.7 Staging
06.7.1 Intraocular Staging
06.7.2 Extraocular staging
06.8 Management
06.8.1 Cryotherapy
06.8.2 Chemotherapy
06.8.3 Photocoagulation
06.8.4 Radiation therapy
06.8.5 Surgery
06.8.6 Thermo therapy

07.Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis

08.Pipeline Analysis
08.1 Key Information of the Pipeline Candidates
08.1.1 NTX-010
08.1.2 Racotumomab
08.1.3 Kevetrin
08.1.4 BL-8040
08.1.5 Melphalan
08.1.6 RNAi Oligonucleotide for Retinoblastoma

09.Market Segmentation by Therapeutic Class of Drugs
09.1 Alkylating Agents
09.2 Antimetabolites
09.3 Microtubule Inhibitors
09.4 Cytotoxic Antibiotics
09.5 Topoisomerase Inhibitors
09.6 Others

10.Market Segmentation by Disease Status

11.Geographical Segmentation

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Baxter
19.2.2 Bristol-Myers Squibb
19.2.3 GlaxoSmithKline
19.2.4 Spectrum Pharmaceuticals
19.3 Other Prominent Vendors

20.Key Vendor Analysis
20.1 Baxter International Inc.
20.1.1 Key Facts
20.1.2 Business Description
20.1.3 Business Segmentation
20.1.4 Business Strategy
20.1.5 Revenue by Business Segmentation
20.1.6 Revenue by Geographical Segmentation
20.1.7 Key Developments
20.1.8 SWOT Analysis
20.2 Bristol-Myers Squibb
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Key Product Offerings
20.2.4 Revenue by Geography
20.2.5 Business Strategy
20.2.6 Key Information
20.2.7 SWOT Analysis
20.3 GlaxoSmithKline
20.3.1 Business Overview
20.3.2 Business Segmentation
20.3.3 Business Segmentation by Revenue 2012 and 2013
20.3.4 Sales by Geography
20.3.5 Key Facts
20.3.6 Pipeline Products
20.3.7 Business Strategy
20.3.8 Key Information
20.3.9 SWOT Analysis

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Classification of Retinoblastoma
Exhibit 3: Symptoms: Percentage Occurrence in Patients
Exhibit 4: Techniques Used for Diagnosing Retinoblastoma
Exhibit 5: Intraocular Staging
Exhibit 6: Extraocular Staging
Exhibit 7: Retinoblastoma: Treatment Options
Exhibit 8: Global Retinoblastoma Market 2014-2019 (US$ million)
Exhibit 9: Pipeline Portfolio
Exhibit 10: Global Retinoblastoma Market by Therapeutic Class of Drugs
Exhibit 11: Global Retinoblastoma Market by Disease Status
Exhibit 12: Global Retinoblastoma Market: Percentage Share of Cases (2014)
Exhibit 13: Global Retinoblastoma Market by Geographical Segmentation 2014
Exhibit 14: Baxter
Exhibit 15: Bristol Myers-Squibb
Exhibit 16: GlaxoSmithKline
Exhibit 17: Spectrum Pharmaceuticals
Exhibit 18: Baxter International Inc. : Business Segmentation
Exhibit 19: Baxter International Inc.: Revenue by Business Segmentation 2013
Exhibit 20: Baxter International Inc.: Revenue by Geographical Segmentation 2013
Exhibit 21: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 22: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 23: GlaxoSmithKline: Business Segmentation 2013
Exhibit 24: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 25: GlaxoSmithKline: Sales by Geography 2013
Exhibit 26: GlaxoSmithKline: Pipeline Products 2013


Baxter, Bristol-Myers Squibb, GlaxoSmithKline, Spectrum Pharmaceuticals, BioLineRx, Cellceutix, Icon Bioscience, Neotropix, RXi Pharmaceuticals, Recombio





★調査レポート[網膜芽細胞腫治療薬の世界市場2015-2019] (Global Retinoblastoma Treatment Market 2015-2019 / IRTNTR6804)販売に関する免責事項
[網膜芽細胞腫治療薬の世界市場2015-2019] (Global Retinoblastoma Treatment Market 2015-2019 / IRTNTR6804)についてEメールでお問い合わせ